Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD.
Kidney Health Research Collaborative and Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA; San Francisco Veterans Affairs Health Care System, San Francisco, CA.
Am J Kidney Dis. 2021 Jul;78(1):75-84.e1. doi: 10.1053/j.ajkd.2020.11.014. Epub 2021 Jan 1.
RATIONALE & OBJECTIVE: Immune activation is fundamental to the pathogenesis of many kidney diseases. Innate immune molecules such as soluble urokinase-type plasminogen activator receptor (suPAR) have been linked to the incidence and progression of chronic kidney disease (CKD). Whether other biomarkers of immune activation are associated with incident kidney failure with replacement therapy (KFRT) in African Americans with nondiabetic kidney disease is unclear.
Prospective cohort.
SETTING & PARTICIPANTS: African American Study of Kidney Disease and Hypertension (AASK) participants with available baseline serum samples for biomarker measurement.
Baseline serum levels of soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ).
Incident KFRT, all-cause mortality.
Cox proportional hazards models.
Among 500 participants with available samples, mean glomerular filtration rate was 44.7mL/min/1.73m, and median urinary protein-creatinine ratio was 0.09g/g at baseline. Over a median follow up of 9.6 years, there were 161 (32%) KFRT and 113 (23%) death events. In models adjusted for demographic and clinical factors and baseline kidney function, each 2-fold higher baseline level of sTNFR1, sTNFR2, and TNF-α was associated with 3.66-fold (95% CI, 2.31-5.80), 2.29-fold (95% CI, 1.60-3.29), and 1.35-fold (95% CI, 1.07-1.71) greater risks of KFRT, respectively; in comparison, each doubling of baseline suPAR concentration was associated with 1.39-fold (95% CI, 1.04-1.86) greater risk of KFRT. sTNFR1, sTNFR2, and TNF-α were also significantly associated with death (up to 2.2-fold higher risks per 2-fold higher baseline levels; P≤0.01). IFN-γ was not associated with either outcome. None of the biomarkers modified the association of APOL1 high-risk status (genetic risk factors for kidney disease among individuals of African ancestry) with KFRT (P>0.05 for interaction).
Limited generalizability to other ethnic groups or causes of CKD.
Among African Americans with CKD attributed to hypertension, baseline levels of sTNFR1, sTNFR2, and TNF-α but not IFN-γ were associated with KFRT and mortality.
免疫激活是许多肾脏疾病发病机制的基础。可溶性尿激酶型纤溶酶原激活物受体(suPAR)等固有免疫分子与慢性肾脏病(CKD)的发生和进展有关。在非裔美国人中,其他免疫激活生物标志物是否与无糖尿病肾病的患者发生需要替代治疗的肾脏衰竭(KFRT)有关尚不清楚。
前瞻性队列研究。
具有可用基线血清样本进行生物标志物测量的非裔美国人肾脏病和高血压研究(AASK)参与者。
可溶性肿瘤坏死因子受体 1(sTNFR1)、sTNFR2、肿瘤坏死因子 α(TNF-α)和干扰素 γ(IFN-γ)的基线血清水平。
新发 KFRT,全因死亡率。
Cox 比例风险模型。
在 500 名具有可用样本的参与者中,平均肾小球滤过率为 44.7mL/min/1.73m,基线时尿蛋白/肌酐比中位数为 0.09g/g。中位随访 9.6 年后,有 161 例(32%)发生 KFRT 和 113 例(23%)死亡事件。在调整人口统计学和临床因素以及基线肾功能的模型中,sTNFR1、sTNFR2 和 TNF-α的基线水平每增加 2 倍,与 KFRT 的风险比分别为 3.66(95%CI,2.31-5.80)、2.29(95%CI,1.60-3.29)和 1.35(95%CI,1.07-1.71);相比之下,suPAR 浓度每增加 2 倍,与 KFRT 的风险比增加 1.39(95%CI,1.04-1.86)。sTNFR1、sTNFR2 和 TNF-α与死亡也显著相关(每增加 2 倍,风险增加高达 2.2 倍;P≤0.01)。IFN-γ与这两种结局均无关。在 APOL1 高危状态(非裔个体的肾脏疾病遗传危险因素)与 KFRT 之间,没有一种生物标志物改变了关联(交互作用 P>0.05)。
对其他种族或 CKD 病因的普遍适用性有限。
在归因于高血压的非裔美国人中,sTNFR1、sTNFR2 和 TNF-α的基线水平,但不是 IFN-γ,与 KFRT 和死亡率有关。